N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies

Fenghua Tan(Central South University), Can Guo(Central South University), Mengyao Zhao(East China University of Technology), Bo Xiang(Central South University), Fang Xiong(Central South University), Zhaoyang Zeng(Gansu University of Traditional Chinese Medicine), Ming Zhou(Central South University), Guiyuan Li(Central South University), Yong Li(Baylor College of Medicine), Xiaoling Li(University of Alabama at Birmingham), Shanshan Zhang(Central South University), Yumin Wang(Harvard University), Wei Xiong(Central South University), Lei Shi(University of Hong Kong), Fuyan Wang(W. L. Gore & Associates (Germany)), Xiayu Li(Third Xiangya Hospital), Yi He(Affiliated Hospital of Southwest Medical University), Zhaojian Gong(Central South University)
Journal of Experimental & Clinical Cancer Research
April 29, 2021
10.1186/s13046-021-01952-4
Cited by 80

Related Papers

Neoantigen vaccine: an emerging tumor immunotherapy
|Molecular Cancer|2019|713
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|677
Effects of environmental pollutants on gut microbiota
|Environmental Pollution|2017|662
Regulatory mechanisms of PD-1/PD-L1 in cancers
|Molecular Cancer|2024|619
MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression
|Journal of Biological Chemistry|2010|429